OncoResponse, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.oncoresponse.com
Non-Small Cell Lung Cancer Clinical Trial Pipeline Sees Significant Growth
The Non-Small Cell Lung Cancer (NSCLC) clinical trial pipeline is experiencing a boom with over 100 companies actively developing more than 120 therapies. Advances in targeted therapies, focusing on genetic mutations like EGFR, ALK, ROS1, BRAF, and MET, are improving treatment outcomes. Recent FDA designations and clinical trial initiations highlight the ongoing innovation and potential for new treatments in the NSCLC domain.
© Copyright 2025. All Rights Reserved by MedPath